AMTX AEMETIS, INC
Industrial Organic Chemicals · Nasdaq · SEC CIK 738214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.6%
TTM net income YoY64.5%
TTM EPS YoY73.5%
Revenue 3-yr CAGR10.8%
Net income 3-yr CAGR—
Margins
Gross margin21.5%
Operating margin7.2%
Net margin-12.5%
FCF margin-14.7%
EBITDA margin11.3%
Returns
ROE—
ROA-11.3%
ROIC (approx.)17.5%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets200.7%
Debt / equity—
Current ratio0.07x
Interest coverage0.32x
Cash quality & payout
Operating cash flow / net income-0.49x
Accruals ratio-16.8%
Payout ratio—
Capex / revenue20.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $197.63M | $267.64M | $186.72M | $28.11M | $211.95M |
| Cost of revenue | $208.75M | $268.22M | $184.70M | $262.05M | $204.01M |
| Gross profit | -$768,000 | -$580,000 | $2.02M | -$5.54M | $7.94M |
| R&D expense | — | — | $152,000 | $180,000 | $88,000 |
| SG&A expense | $36.45M | $39.84M | $39.42M | $28.69M | $23.68M |
| Operating income | -$37.22M | -$40.42M | -$37.40M | -$34.40M | -$15.82M |
| Interest expense | $52.91M | $46.62M | $39.52M | $28.77M | $24.06M |
| Pretax income | -$95.75M | -$98.37M | -$100.16M | -$106.70M | -$47.27M |
| Income tax | -$18.75M | -$10.83M | -$53.74M | $1.05M | -$128,000 |
| Net income | -$77.00M | -$87.54M | -$46.42M | -$107.76M | -$47.15M |
| EBITDA | -$27.59M | -$32.03M | -$30.47M | -$28.87M | -$10.38M |
| EPS (basic) | -1.28 | -1.91 | -1.22 | -3.12 | -1.54 |
| EPS (diluted) | -1.28 | -1.91 | -1.22 | -3.12 | -1.54 |
| Weighted avg. shares (diluted) | 59.98M | 45.90M | 38.06M | 34.59M | 30.68M |
| Balance sheet | |||||
| Cash & equivalents | $4.89M | $898,000 | $2.67M | $4.31M | $7.75M |
| Receivables | — | — | — | $1.26M | $1.57M |
| Inventory | $11.63M | $25.44M | $18.29M | $4.66M | $5.13M |
| Current assets | $26.87M | $44.70M | $36.40M | $18.14M | $20.69M |
| PP&E, net | $219.72M | $199.39M | $195.11M | $180.44M | $135.10M |
| Total assets | $259.84M | $259.30M | $243.41M | $207.11M | $160.83M |
| Current liabilities | $371.26M | $143.97M | $84.39M | $88.28M | $65.33M |
| Short-term debt | $317.87M | $90.53M | $37.03M | $49.22M | $22.78M |
| Long-term debt | $63.90M | $247.53M | $257.69M | $197.02M | $165.99M |
| Total debt | $381.76M | $338.06M | $294.72M | $246.24M | $188.77M |
| Total liabilities | $566.67M | $523.23M | $460.38M | $408.97M | $281.07M |
| Shareholders' equity | -$306.83M | -$263.93M | -$216.98M | -$201.85M | -$120.24M |
| Net debt | $376.87M | $337.16M | $292.05M | $241.93M | $181.02M |
| Shares outstanding | 66.19M | 51.14M | 40.97M | 35.87M | 33.46M |
| Cash flow statement | |||||
| Operating cash flow | $3.26M | -$32.93M | $13.82M | -$22.87M | -$20.65M |
| Capital expenditure | $26.00M | $20.25M | $33.12M | $39.16M | $26.65M |
| Free cash flow | -$22.74M | -$53.18M | -$19.29M | -$62.02M | -$47.30M |
| Investing cash flow | -$25.59M | -$14.15M | -$23.69M | -$31.31M | -$22.89M |
| Financing cash flow | $26.41M | $44.62M | $9.09M | $53.63M | $50.70M |
| Depreciation & amortization | $9.62M | $8.39M | $6.93M | $5.54M | $5.45M |
| Stock-based compensation | $5.77M | $8.31M | $7.66M | $6.41M | $3.93M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.